Compare Broadcom Inc (AVGO) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Broadcom Inc vs Charles River Laboratories Intl. Inc — how do they compare? Broadcom Inc trades at $415.21 (market cap $1.98T), while Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B). The key difference: Broadcom Inc is far larger — about 147.1× Charles River Laboratories Intl. Inc's market cap, and Broadcom Inc pays a 0.62% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| AVGO | CRL | |
|---|---|---|
Market Cap | $1.98T | $13.46B |
Sector | Technology | Health |
52-Week High | $481.57 | $282.00 |
52-Week Low | $289.60 | $145.57 |
Enterprise Value | $2.02T | $16.30B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Broadcom (AVGO) trades at $414.83, down 1.79% on the day, amid strong fundamentals including a 38.85% net income margin and consistent earnings beats. Technical analysis shows a bullish trend with key support at $412 and resistance at $422. The company reported robust cash flow from operations of $27.54 billion in 2025 and projects AI semiconductor revenue exceeding $100 billion by 2027, per CEO Hock Tan's reaffirmed forecast (The Motley Fool, 2026-08-11).
Outlook remains positive with 86% analyst buy ratings and a $510.21 consensus price target, though high valuation multiples (P/E 69.23) and competitive pressures in AI chips pose risks. The stock's growth is supported by booked AI revenue and strong cash generation, offering upside if execution continues.
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
